# US 2022/0033910 A1 · Method for Detecting Liver Diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033910 A1
- Document ID: US20220033910A1
- Status: Published application
- Kind: A1
- Application number: 17/274,955
- Filed: 2019-09-11
- Published: 2022-02-03
- Earliest claimed: 2018-09-11
- Assignees: The General Hospital Corporation; President and Fellows of Harvard College
- Applicants: The General Hospital Corporation; President and Fellows of Harvard College
- Inventors: David T. Ting; Irun Bhan; Kelly Mosesso; Martin Aryee
- Web page: https://patentgrep.com/patent/US20220033910A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 1/34: Purifying; Cleaning {(processes or apparatus for extracting or separating nucleic acids from biological samples C12N15/1003)}
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- G01N 33/582: {with fluorescent label}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods for diagnosing, determining, or monitoring liver diseases and conditions based on the blood concentration of circulating epithelial cells in and their gene expression.

## Claims

### Claim 1

A method, comprising measuring expression levels of hepatocellular carcinoma (HCC) classifier genes in circulating epithelial cells (CECs) of a subject, wherein the HCC classifier genes comprise one or more of TESC, OSBP2, SLC6A8, SEPT5, F2RL3, E2F1, EZH2, CDC20, CCNA2, CCNB1, PLXNB3, CDC6, MYBL2, APOBEC3B, SPP1, AKR1B10, TOP2A, ASPM, SLC6A9, RECQL4, NUSAP1, PLVAP, FMO1, PDZK1IP1, and FBXO32.

### Claim 2 (depends on 1)

The method of claim 1, wherein the HCC classifier genes consist of one or more of TESC, OSBP2, SLC6A8, SEPT5, F2RL3, E2F1, EZH2, CDC20, CCNA2, CCNB1, PLXNB3, CDC6, MYBL2, APOBEC3B, SPP1, AKR1B10, TOP2A, ASPM, SLC6A9, RECQL4, NUSAP1, PLVAP, FMO1, PDZK1IP1, and FBXO32.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the HCC classifier genes consist of TESC, OSBP2, SLC6A8, SEPT5, F2RL3, E2F1, EZH2, CDC20, CCNA2, CCNB1, PLXNB3, CDC6, MYBL2, APOBEC3B, SPP1, AKR1B10, TOP2A, ASPM, SLC6A9, RECQL4, NUSAP1, PLVAP, FMO1, PDZK1IP1, and FBXO32.

### Claim 4 (depends on 1)

The method of claim 1, wherein the HCC classifier genes further comprise one, two, three or more additional genes selected from the group consisting of ACTG2, ADM2, AFP, AGR2, ALDH3A1, ALPK3, AMIGO3, ANKRD65, ANLN, AP1M2, ARHGAP11A, ARHGEF39, ASF1B, ASPHD1, AURKA, AXIN2, BAIAP2L2, BEX2, C15orf48, C1orf106, C1QTNF3, C6orf223, CA12, CA9, CAMK2N2, CAP2, CBX2, CCDC170, CCDC28B, CCDC64, CCNE2, CCNF, CD109, CD34, CDC25A, CDC7, CDCA5, CDCA8, CDH13, CDK1, CDKN2A, CDKN2C, CDT1, CELF6, CENPF, CENPH, CENPL, CENPU, CENPW, CKB, CNNM1, COL15A1, COL4A5, COL7A1, COL9A2, CRIP3, CSPG4, CTNND2, CXorf36, CYP17A1, DLK1, DMKN, DSCC1, DTL, DUOX2, ECT2, EEF1A2, EFNA3, EPHB2, EPPK1, ETV4, FABP4, FAM111B, FAM3B, FAM83D, FANCD2, FANCI, FBXL18, FERMT1, FGF19, FLNC, FLVCR1, FOXD2-AS1, FOXM1, FXYD2, GABRE, GAL3ST1, GCNT3, GINS1, GJC1, GMNN, GNAZ, GOLGA2P7, GPC3, GPR64, GPSM1, HRCT1, IGF2BP2, IGSF1, IGSF3, IQGAP3, ITGA2, ITPKA, KIAA0101, KIF11, KIFC1, KIFC2, KNTC1, KRT23, LAMA3, LEF1, LGR5, LINC00152, LINGO1, LPL, LRRC1, LYPD1, MAD2L1, MAGED4, MAGED4B, MAPK12, MAPK8IP2, MAPT, MCM2, MDGA1, MDK, MFAP2, MISP, MKI67, MMP11, MNS1, MPZ, MSC, MSH5, MTMR11, MUC13, MUC5B, MYH4, NAALADL1, NAV3, NCAPG, NDUFA4L2, NEB, NKD1, NMB, NOTCH3, NOTUM, NPM2, NQO1, NRCAM, NT5DC2, NTS, OBSCN, OLFML2A, OLFML2B, PAQR4, PEG10, PI3, PLCE1, PLCH2, PLK1, PLXDC1, PODXL2, POLE2, PPAP2C, PRC1, PTGES, PTGFR, PTHLH, PTK7, PTP4A3, PTTG1, PYCR1, RACGAP1, RBM24, RHBG, RNF157, ROBO1, RP4-800G7.2, RPS6KL1, RRM2, S100A1, SCGN, 5-Sep, SERPINA12, SEZ6L2, SFN, SGOL2, SLC22A11, SLC51B, SLC6A2, SNCG, SOAT2, SP5, SPARCL1, SPINK1, STIL, STK39, SULT1C2, TCF19, TDGF1, THY1, TK1, TMC5, TMEM132A, TMEM150B, TNFRSF19, TNFRSF25, TONSL, TPX2, TRIM16, TRIM16L, TRIM31, TRIM45, TTC39A, UBD, UBE2C, UBE2T, UGT2B11, USH1C, VSIG10L, WDR62, WDR76, and ZWINT.

### Claim 5 (depends on 1, 2, 3, 4)

A method for detecting the presence of HCC in a subject having chronic liver disease (CLD), the method comprising:
(a) measuring expression levels of the HCC classifier genes of any one of claims 1-4 in CECs of the subject; and
(b) comparing the expression levels of the HCC classifier genes in the CECs of the subject with reference expression levels of HCC classifier genes thereby determining the presence of HCC.

### Claim 6 (depends on 5)

The method of claim 5, wherein the expression levels of HCC classifier genes are used to calculate a HCC score, and the calculated HCC score is compared with a reference score, wherein the presence of HCC is determined based on the presence of a HCC score above the reference score.

### Claim 7 (depends on 6)

The method of claim 6, wherein the HCC score is calculated using a random forest analysis.

### Claim 8 (depends on 5)

The method of claim 5, wherein the expression levels of HCC classifier genes are compared with the reference expression levels of HCC classifier genes using a multivariate logistic regression modeling approach.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the expression levels of HCC classifier genes in circulating epithelial cells (CECs) are measured by:
(a) obtaining a sample comprising blood from the subject;
(b) removing red blood cells, platelets, and plasma from the sample by size-based exclusion;
(c) removing white blood cells (WBCs) from the sample by magnetophoresis; and
(d) measuring the expression of a set of genes in the CECs using RNA-sequencing, qRT-PCT, RNA in situ hybridization, protein microarray, or mass spectrometry and protein profiling.

### Claim 10 (depends on 5, 6, 7, 8, 9)

The method of any one of claims 5-9, wherein the HCC being detected is an early stage HCC.

### Claim 11 (depends on 5, 6, 7, 8, 9)

The method of any one of claims 5-9, wherein the HCC being detected is a late stage HCC.

### Claim 12 (depends on 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 5-11 further comprising:
(a) confirming or having confirmed the presence of HCC in the patient by ultrasound imaging, dynamic CT, MRI imaging, needle biopsy, and/or biopsy; and
(b) if the presence of HCC in the patient is confirmed, treating or having the subject treated for HCC by surgical removal of the HCC tissue, radiofrequency ablation of the HCC tissue, embolization of the HCC tissue; embolization of HCC tissue, chemotherapy, and/or cryotherapy.

### Claim 13 (depends on 6, 7)

A method of monitoring a subject having CLD for development of HCC, the method comprising:
(a) performing the method of claim 6 or 7 at an initial time point, and if the HCC score is below the reference score, then
(b) performing the method of claim 6 or 7 at one or more subsequent time points.

### Claim 14 (depends on 13)

The method of claim 13, wherein step (b) is performed at one or more subsequent time points until the presence of HCC is determined.

### Claim 15 (depends on 13, 14)

The method of claim 13 or 14, wherein the initial and each subsequent time point is about three months, six months, or a year apart.

### Claim 16

A method of distinguishing between the presence of early stage liver fibrosis and late stage liver fibrosis in a subject having CLD, the method comprising:
(a) detecting a concentration of CECs in a blood sample of the subject;
(b) comparing the concentration of CECs in the blood sample of the subject with a reference value;
(c) diagnosing the subject with early stage fibrosis if the subject has concentration of CECs in the blood sample that is below the reference value; and
(d) diagnosing the subject with late stage fibrosis if the subject has concentration of CECs in the blood sample that is above the reference value.

### Claim 17 (depends on 16)

The method of claim 16, wherein the subject has hepatitis B.

### Claim 18 (depends on 16, 17)

The method of claim 16 or 17, wherein the concentration of CECs is measured by immunofluorescence.

### Claim 19 (depends on 16, 17, 18)

The method of any one of claims 16-18, wherein the concentration of CECs is measured by detecting glypican-3 (GPC3) and/or cytokeratins (CKs).

### Claim 20 (depends on 16, 17, 18, 19)

A method of monitoring a subject having CLD for development of advanced fibrosis, the method comprising:
(a) performing the method of any one of claims 16-19; and if the concentration of CECs in the blood sample of the subject is lower than the reference value, then
(b) performing the method of any one of claims 16-19 at one or more subsequent time points.

### Claim 21 (depends on 20)

The method of claim 20, wherein step (b) is performed at one or more subsequent time points until the subject is diagnosed with late stage fibrosis.

### Claim 22 (depends on 16, 17, 18, 19, 20)

The method of any one of claims 16-20, wherein the initial and each subsequent time point is about three months, six months, or a year apart.

### Claim 23 (depends on 6, 7, 16, 17, 18, 19)

A method of monitoring a subject having CLD being treated to prevent the progression of fibrosis or HCC, the method comprising:
(a) performing the method of any one of claims 16-19; and if the concentration of CECs in the blood sample of the subject is lower than the reference value, then performing the method of any one of claims 16-19 at one or more subsequent time point; and
(b) performing the method of claim 6 or 7 at an initial time point, and if the expression levels of the HCC score is below the reference score, then performing the method of claim 6 or 7 at one or more subsequent time points.

### Claim 24 (depends on 23)

The method of claim 23, wherein step (a) is performed at one or more subsequent time points until the subject is diagnosed with late stage fibrosis, and/or wherein step (b) is performed at one or more subsequent time points until the presence of HCC is determined.

### Claim 25 (depends on 23, 24)

The method of claim 24, wherein the first initial and each subsequent time point for performing step (a) or step (b) of claim 23 is about three months, six months, or a year apart, and the second initial and each subsequent time point is about three months, six months, or a year apart.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the CECs in the blood are purified or enriched using a microfluidic device.

### Claim 27 (depends on 26)

The method of claim 26, wherein the microfluidic device is an iChip device.
